Dossier assessment
Dolutegravir/abacavir/lamivudine (HIV infection in children) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Dolutegravir/abacavir/lamivudine (HIV infection in children) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Dolutegravir/abacavir/lamivudine (HIV infection in children) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Children with HIV-1 infection
Result of dossier assessment:
- Treatment-naive children aged 2 to < 6 years: added benefit not proven
- Treatment-naive children aged 6 to < 12 years: added benefit not proven
- Treatment-experienced children aged 2 to < 12 years: added benefit not proven
Project details
- Project no.
- A23-17
- Commission
- Commission awarded on 01.03.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Dolutegravir/abacavir/lamivudine - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed